Abstract
Cardioversion is widely used in patients with atrial fibrillation (AF) and atrial flutter when a rhythm control strategy is pursued. We sought to summarize the current evidence on this important area of clinical management of patients with AF including electrical and pharmacological cardioversion, peri-procedural anticoagulation and thromboembolic complications, success rate, and risk factors for recurrence to give practical guidance.
Original language | English |
---|---|
Journal | Europace |
Volume | 22 |
Issue number | 8 |
Pages (from-to) | 1149-1161 |
ISSN | 1099-5129 |
DOIs | |
Publication status | Published - 1. Aug 2020 |
Bibliographical note
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.Keywords
- Anticoagulation
- Atrial fibrillation
- Atrial flutter
- Electrical cardioversion
- Pharmacological cardioversion
- Thromboembolism